Publications by authors named "Markus Abt"

Claim this Profile
E
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Kirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Markus Abt

NPJ Digit Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities and challenges with decentralized trials in Neuroscience.
Hans Ulrich Burger, Tom Van de Casteele, Khadija Rerhou Rantell, Patricia Corey-Lisle, Nikolaos Sfikas, Markus Abt

Biom J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Biomarkers of Inflammation and Endothelial Activation in Diabetic Retinopathy.
Federica Storti, Jennifer Pulley, Pascal Kuner, Markus Abt, Ulrich F O Luhmann

Transl Vis Sci Technol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms.
Daniel Umbricht, Markus Abt, Paul Tamburri, Christopher Chatham, Štefan Holiga

Biol Psychiatry Glob Open Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of valganciclovir on spermatogenesis in renal transplant patients - results of a multicenter prospective nonrandomized study.
Patrick McLeroth, Darius A Paduch, Markus Abt, Richard Hughes, Suzanne Moore

Transpl Int· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring.
Markus Abt, Theo Dinklo, Andreas Rothfuss, Elisabeth Husar, Robert Dannecker

Clin Pharmacol Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil
.
Bruno Reigner, Susan Grange, Darren Bentley, Ludger Banken, Markus Abt

Int J Clin Pharmacol Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development.
David H Manner, Chakib Battioui, Stefan Hantel, B Nhi Beasley, Lee-Jen Wei, Markus Abt

Am Heart J· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Peter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, Elena Guerini, Markus Abt

J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Peter N Morcos, Katrijn Bogman, Stanislas Hubeaux, Carolina Sturm-Pellanda, Thorsten Ruf, Markus Abt

Cancer Chemother Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.
Kaspar Rufibach, Paul Jordan, Markus Abt

J Biopharm Stat· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development.
Kaspar Rufibach, Hans Ulrich Burger, Markus Abt

Pharm Stat· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Vascular Calcification Accelerate Inflammation?: A Substudy of the dal-PLAQUE Trial.
Francis R Joshi, Nikil K Rajani, Markus Abt, Mark Woodward, Jan Bucerius

J Am Coll Cardiol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects.
Carolina Sturm-Pellanda, Markus Abt, Patricia Sanwald-Ducray, Christophe Schmitt

Clin Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Heidemarie Kletzl, Mylene Giraudon, Patricia Sanwald Ducray, Markus Abt, Marta Hamilton

Anticancer Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin.
Christophe Schmitt, Markus Abt, Cornelia Ciorciaro, Dorothee Kling, Candice Jamois

J Cardiovasc Pharmacol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
Gregory G Schwartz, Markus Abt, Weihang Bao, David DeMicco, David Kallend

J Am Coll Cardiol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.
Eric J Niesor, Gregory G Schwartz, Anne Perez, Andrea Stauffer, Alexandre Durrwell, Markus Abt

Cardiovasc Drugs Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study.
Venkatesh Mani, Mark Woodward, Daniel Samber, Jan Bucerius, Ahmed Tawakol, Markus Abt

Int J Cardiovasc Imaging· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study.
Eric J Niesor, Kekulawalage Gauthamadasa, R A Gangani D Silva, Gabriela Suchankova, David Kallend, Markus Abt

Lipids· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter

N Engl J Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Issues in the assessment of non-inferiority: perspectives drawn from case studies.
H Ulrich Burger, Ulrich Beyer, Markus Abt

Pharm Stat· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Jianguo Zhi, Eric Chen, Pierre Major, Ivon Burns, Bridget Robinson, Markus Abt

Cancer Chemother Pharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt

Lancet· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Michael Derks, Hitoshi Kawamura, Markus Abt, Georgina Meneses-Lorente, Mary Phelan

Clin Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis